Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET

Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET

Show other versions (2)

A 71 year old female with multiple myeloma presented with back pain seven year after autologous stem cell transplant. Skeletal bone survey and magnetic resonance imaging did not show a relapse that was evidenced by CT/PET. Lenalidomide as single agent induced a complete disappearance of the lesions...

Full description

Bibliographic Details
Main Authors:	Alessandro Gozzetti, Vania Rossi, Alfonso Cerase, Giulia Papini, Marzia Defina, Monica Bocchia
Format:	Article
Language:	English
Published:	PAGEPress Publications 2014-08-01
Series:	Mediterranean Journal of Hematology and Infectious Diseases
Subjects:	lenalidomide myeloma imaging
Online Access:	https://mjhid.org/index.php/mjhid/article/view/1836

Similar Items

Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2012-01-01)

Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2012-06-01)

Therapeutic advancements in multiple myeloma
by: Alessandro eGozzetti, et al.
Published: (2014-09-01)

LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE
by: Patrizia Tosi
Published: (2013-06-01)

Simultaneous myelodisplasia and multiple myeloma successfully treated with lenalidomide
by: Alessandro Gozzetti, et al.
Published: (2014-08-01)

LENALIDOMIDE RETREATMENT IN A PATIENT WITH RELAPSED MULTIPLE MYELOMA WHO HAD PREVIOUSLY RESPONDED TO LENALIDOMIDE
by: Vincenzo Federico
Published: (2014-08-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
by: Maryam Pourabdollah, et al.
Published: (2016-11-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Efficacy of Lenalidomide plus Low-Dose Dexamethasone in Thai Patients with Relapsed and/or Refractory Multiple Myeloma
by: Chutima Kunacheewa, et al.
Published: (2021-04-01)

Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma
by: Schmidt-Wolf, Ingo G. H., et al.
Published: (2011-01-01)

A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in Taiwan
by: Shang-Yi Huang, et al.
Published: (2017-09-01)

Lenalidomide with dexamethasone to multiple myeloma patients relapsing from bortezomib-based induction therapies: A prospective, observational study
by: Tran-Der Tan, et al.
Published: (2020-01-01)

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
by: Jiri Minarik, et al.
Published: (2021-01-01)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
by: Cirino Botta, et al.
Published: (2021-04-01)

Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials
by: Shu-Kai Qiao, et al.
Published: (2015-01-01)

Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide
by: Schoenbeck KL, et al.
Published: (2020-05-01)

Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience
by: Vera A. Zherebtsova, et al.
Published: (2021-07-01)

Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis
by: Francesca Bonello, et al.
Published: (2019-11-01)

COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.
by: Monia Marchetti, et al.
Published: (2021-04-01)

COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.
by: Monia Marchetti, et al.
Published: (2021-04-01)

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01)

Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide
by: Wang H, et al.
Published: (2021-04-01)

Chidamide-Induced Accumulation of Reactive Oxygen Species Increases Lenalidomide Sensitivity Against Multiple Myeloma Cells
by: Jiang D, et al.
Published: (2021-07-01)

Chemomobilization with cyclophosphamide and filgrastim in multiple myeloma patients following lenalidomide treatment
by: Gerfen, Ashlee
Published: (2012)

Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size
by: Celine Berthon, et al.
Published: (2020-01-01)

Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile
by: Susana Aceituno, et al.
Published: (2018-06-01)

Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma
by: Catherine S. Y. Lecat, et al.
Published: (2021-07-01)

Brain abscesses caused by Nocardia paucivorans in a multiple myeloma patient treated with lenalidomide and dexamethasone: a case report and review of literature.
by: Jacopo Monticelli, et al.
Published: (2014-12-01)

Combined Use of Ninjin'yoeito Improves Subjective Fatigue Caused by Lenalidomide in Patients With Multiple Myeloma: A Retrospective Study
by: Tomoki Ito, et al.
Published: (2018-08-01)

Database study of lenalidomide (Revlimid) in Germany: monitoring off-label use [Monitoring des Off-Label-Use von Lenalidomid (Revlimid) in Deutschland]
by: Dörks, Michael, et al.
Published: (2013-07-01)

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
by: Marc-Andrea Baertsch, et al.
Published: (2021-09-01)

miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma
by: Daniele Caracciolo, et al.
Published: (2021-08-01)

Ameliorating the antitumor activity of lenalidomide using PLGA nanoparticles for the treatment of multiple myeloma
by: Veera Venkata Satyanarayana Reddy Karri, et al.
Published: (2017-06-01)

Synthesis of hapten and preparation of specific polyclonal antibody with high affinity for lenalidomide, the potent drug for treatment of multiple myeloma
by: Darwish Ibrahim A, et al.
Published: (2012-10-01)

PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION
by: R. Yagudina, et al.
Published: (2015-03-01)

Chemomobilization with Cyclophosphamide and Filgrastim in Multiple Myeloma Patients Following Lenalidomide Treatment
by: Gerfen, Ashlee, et al.
Published: (2012)

B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review
by: Ryan B. Sinit, et al.
Published: (2019-11-01)

Daratumumab efficacy in extramedullary orbital myeloma
by: Alessandro Gozzetti, et al.
Published: (2020-12-01)